Xeris Biopharma Holdings, Inc.
XERS
$5.94
-$0.14-2.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 83.13M | 85.81M | 74.38M | 71.54M | 60.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.13M | 85.81M | 74.38M | 71.54M | 60.12M |
| Cost of Revenue | 10.57M | 10.95M | 11.00M | 11.90M | 8.73M |
| Gross Profit | 72.55M | 74.86M | 63.38M | 59.64M | 51.39M |
| SG&A Expenses | 53.14M | 47.50M | 46.46M | 44.39M | 44.02M |
| Depreciation & Amortization | 2.71M | 2.71M | 2.71M | 2.71M | 2.71M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.21M | 69.03M | 67.65M | 67.06M | 63.21M |
| Operating Income | 7.92M | 16.77M | 6.73M | 4.48M | -3.09M |
| Income Before Tax | 2.23M | 11.08M | 621.00K | -1.93M | -9.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.23M | 11.08M | 621.00K | -1.93M | -9.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.23M | 11.08M | 621.00K | -1.93M | -9.22M |
| EBIT | 7.92M | 16.77M | 6.73M | 4.48M | -3.09M |
| EBITDA | 10.96M | 19.82M | 9.78M | 7.52M | -65.00K |
| EPS Basic | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 |
| Normalized Basic EPS | 0.01 | 0.04 | 0.00 | -0.01 | -0.04 |
| EPS Diluted | 0.01 | 0.06 | 0.00 | -0.01 | -0.06 |
| Normalized Diluted EPS | 0.01 | 0.04 | 0.00 | -0.01 | -0.04 |
| Average Basic Shares Outstanding | 170.52M | 165.96M | 163.65M | 159.46M | 152.45M |
| Average Diluted Shares Outstanding | 177.63M | 180.07M | 177.62M | 159.46M | 152.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |